





Supplementary Figure 1


All eligible patients

Median PFS: 8.5 months (95%CI 7.8–9.2)



Patients at risk 754 464 256 154 107 73 27 11 3 0 0


All eligible patients




Patients at risk

Cohort A	539	360	203	119	83	56	21	8	1	0	0
Cohort B	215	104	53	35	24	17	6	3	2	0	0


Supplementary Figure 2b



Supplementary Figure 2c



Supplementary Figure 2d



Patients at risk

First-line therapy	133	70	38	24	19	13	5	2	1	0	0
Second-line therapy	82	34	15	11	5	4	1	1	1	0	0

Figure legends

Supplementary Fig. 1 Patient disposition. Cohorts A and B comprised patients with hormone receptor–positive breast cancer and triple-negative breast cancer, respectively.

Supplementary Fig. 2 Progression-free survival in the eligible patient population: **a**, all eligible patients; **b**, cohort A (patients with hormone receptor–positive breast cancer) versus cohort B (patients with triple-negative breast cancer); **c**, all eligible patients receiving first-line versus second-line therapy; **d**, first-line versus second-line therapy in cohort A; **e**, first-line versus second-line therapy in cohort B.